Croda International (CRDA)

Sector:

Industrial Chemicals

Index:

FTSE 100

4,394.00p
   
  • Change Today:
    123.00p
  • 52 Week High: 5,375.00p
  • 52 Week Low: 4,070.00p
  • Currency: UK Pounds
  • Shares Issued: 128.89m
  • Volume: 368,269
  • Market Cap: £5,663m
  • RiskGrade: 195

SkinBioTherapeutics strikes deal with chemicals giant Croda

By Josh White

Date: Wednesday 20 Nov 2019

LONDON (ShareCast) - (Sharecast News) - Skin health-focussed life sciences company SkinBioTherapeutics has signed a commercial agreement with speciality chemicals giant Croda International, it announced on Wednesday.
The AIM-traded firm said that under the terms of the agreement, its proprietary 'SkinBiotix' platform would be paired with Croda's expertise in the development and commercialisation of "unique, sustainable" cosmetic ingredients, focusing specifically on the growing skincare actives market.

Sederma, part of Croda, is a specialist in bioactive ingredients for the cosmetic industry, and would be responsible for the development, manufacture and commercialisation of the SkinBiotix technology.

As design-and-build of the active ingredient is carried out, there would be concurrent testing in focussed application areas which would be detailed in further, additional agreements, the company explained.

Any licensed products resulting from the agreement would be sold to Croda's global portfolio of personal care customers.

SkinBioTherapeutics said it would be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership, which would subsequently be agreed on successful development of the technology.

Sales and distribution rights were for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors, the board added.

"The focus of this year has been on commercialisation, therefore, we are delighted that the first announcement has been a significant deal with a world-leading company such as Croda and being able to utilise the expertise within Sederma," said SkinBioTherapeutics chief executive officer Stuart Ashman.

"This partnership brings together our innovation in the microbiome space and Sederma's track record of developing world-class cosmetic ingredients.

"As we have stated before, we intend to build a significant portfolio around our core technology across multiple sectors to create further value for our shareholders - this deal with Croda is just the beginning."

At 1554 GMT, shares in SkinBioTherapeutics were up 0.6% at 16.85p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CRDA Market Data

Currency UK Pounds
Share Price 4,394.00p
Change Today 123.00p
% Change 2.88 %
52 Week High 5,375.00p
52 Week Low 4,070.00p
Volume 368,269
Shares Issued 128.89m
Market Cap £5,663m
RiskGrade 195

CRDA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.39% below the market average88.39% below the market average88.39% below the market average88.39% below the market average88.39% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
23.45% above the market average23.45% above the market average23.45% above the market average23.45% above the market average23.45% above the market average
44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average44.44% above the sector average
Income
81.62% below the market average81.62% below the market average81.62% below the market average81.62% below the market average81.62% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average

What The Brokers Say

Strong Buy 2
Buy 1
Neutral 13
Sell 0
Strong Sell 3
Total 19
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CRDA Dividends

  Latest Previous
  Final Interim
Ex-Div 16-Apr-20 22-Aug-19
Paid 28-May-20 02-Oct-19
Amount 50.50p 39.50p

Trades for 09-Apr-2020

Time Volume / Share Price
16:10 59 @ 4,394.00p
16:10 54 @ 4,396.00p
16:09 46 @ 4,396.00p
16:09 31 @ 4,396.00p
16:09 2 @ 4,396.00p

CRDA Key Personnel

Chair Anita Frew

Top of Page